

Addressing Lung Cancer Biomarker Testing Through Project ECHO

Post-Session Resources Session 1

6.28.2021



This document compiles some of the key resources mentioned during Session 1, [Understanding the Barriers to Biomarker Testing](#). To review all publications, articles, or commentaries mentioned, we recommend reviewing the presentation recording and PowerPoint presentation. All slides and recordings can be found [here](#).

Case Presentation and Feedback Forum

- ✓ [Post Session Feedback Forum](#): Feel free to provide additional feedback confidentially on Session 1 and or the entire ECHO Series beyond the post-session polls through this forum. [Link](#)
- ✓ [Case Presentation Interest Survey](#): You can use this link to sign up for your preferred case presentation date, choosing between those that are state specific or the combined sessions. A member of the ACS Hub team will confirm your date and will work with you to ensure your experience is both valuable and easy. [Link](#)

Highlights of Session Resources (Literature or Resources Mentioned During the Didactic or Case Presentation)

- ✓ [Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities](#) [Link](#)
- ✓ [Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study](#) [Link](#)
- ✓ [Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study](#) [Link](#)
- ✓ [Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer \(NEJM publication for the ADAURA trial\)](#) [Link](#)
- ✓ [Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology](#) [Link](#)
- ✓ [NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\) Non-Small Cell Lung Cancer Version 4.2021-March 3, 2021](#) [Link](#)
- ✓ [National Lung Cancer Roundtable Stakeholder Confessionals](#) [Link](#)
- ✓ [National Lung Cancer Roundtable 2020 Biomarker Summit Summary](#) [Link](#)
- ✓ [IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data](#) [Link](#)

New Tool/Resource

- ✓ [The Biomarker Testing Implementation Roadmap for Advanced Non-Small Cell Lung Cancer \(NSCLC\) by Association of Community Cancer Centers \(ACCC\)](#) [Link](#)

About the Tool: an innovative learning tool by ACCC that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.